Yes, voxelotor, marketed under the brand name Oxbryta, is FDA approved. The U.S. Food and Drug Administration (FDA) approved voxelotor on November 25, 2019, for the treatment of sickle cell disease in adults and children aged 12 years and older. The approval was expanded in December 2021 to include children as young as 4 years old.
Voxelotor is a medication used to treat sickle cell disease, a genetic disorder that causes red blood cells to become misshapen and break down. Voxelotor works by inhibiting hemoglobin polymerization, which is a key factor in the pathophysiology of sickle cell disease. This action helps reduce hemolysis (breakdown of red blood cells) and improve anemia.
Voxelotor is available in oral tablet forms and is usually taken once daily. The dosage varies depending on the patient's age and weight:
The medication can be taken with or without food. It is essential to follow the prescribed dosing instructions and not to crush, chew, or break the tablets. The tablets for oral suspension should be mixed with room temperature clear liquid just before taking.
Common Side Effects
Serious Side Effects
Voxelotor can interact with several medications, including:
It is crucial to inform your healthcare provider about all medications you are taking to avoid potential interactions.
Voxelotor (Oxbryta) is an FDA-approved medication for the treatment of sickle cell disease in patients aged 4 years and older. Approved on November 25, 2019, it offers a significant therapeutic option to manage this chronic and often debilitating condition. As with any medication, it is essential to follow the prescribed dosage, be aware of potential side effects, and communicate with your healthcare provider about any other medications you are taking.
In the Synapse database, you can stay updated on the latest research and development advances of all drugs. This service is accessible anytime and anywhere, with updates available daily or weekly. Use the "Set Alert" function to stay informed. Click on the image below to embark on a brand new journey of drug discovery!